Dr. Charles Roberts is chief investment strategist of ARK Investment Management LLC (ARK Invest). As Chief Investment Strategist, Charles is responsible for providing input for research and strategies in both public and private markets, with a particular focus on AI and multiomics. In addition, Charles plays a key role in the strategy and execution of ARK's venture capital efforts. Charles joined ARK in 2023.

Before ARK, Charles's background was as a deep tech entrepreneur and serial founder with a focus on AI for social benefit, primarily in healthcare. He co-founded a number of companies, including Freenome, a Bay Area-based company employing approximately 500 people that works to save lives through earlier detection of cancer. Freenome is currently completing one of the world's largest ever registrational clinical studies in ~42,000 subjects, raising $1.35 billion from leading investors including Roche, Novartis, Fidelity, Janus Henderson and venture capital funds including a16z, GV and DCVC. Charles also co-founded other AI/tech bio companies, including (as chairman) Relation Therapeutics Inc., also backed by DCVC, co-led by NVIDIA, plus Deerfield and other leading investors, with whom Relation will seed $60 million in 2024 completed. He co-founded biotech companies Agalimmune (acquired by a Nasdaq-listed biotech) and Centauri Tx, backed by Novo and Boerhinger Ingelheim, co-founded with the Nobel Prize-winning inventor of PCR. Charles also co-founded a non-invasive prenatal testing company that commercialized the first CE-marked NIPT test using next-generation sequencing. He has served as an advisor to OSE, the University of Oxford's ~$1 billion spin-out fund, and led a family office for a venture studio.

Subjects:

– Investments in disruptive technologies
– Future of AI and Multiomics
– Role of AI in investment decisions

#ARKInvest #VentureCapital #DisruptiveInnovation #AI #Biotech

Please take the opportunity to connect and share this video with your friends and family if you find it helpful.